Autors:

CiteWeb id: 20090000195

CiteWeb score: 3198

DOI: 10.1056/NEJMoa0805019

Background We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab. Methods We randomly assigned patients with epidermal growth factor receptor–positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab. The primary end point was progression-free survival. Results A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone. The hazard ratio for progression-free survival in the cetuximab–FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048). There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31). There was a significant interaction between treatment group and KRAS ...

The publication "Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer" is placed in the Top 10000 of the best publications in CiteWeb. Also in the category Medicine it is included to the Top 1000. Additionally, the publicaiton "Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer" is placed in the Top 1000 among other scientific works published in 2009.
Links to full text of the publication: